novartis glp-1 receptor agonist Frontiers “Weighing In” on GLP-1 Receptor

As mentioned above, 70% of diabetes patients discontinue GLP-1 treatment within two years

We chose to collect data from 2007 onwards as both GLP-1 RAs and DPP-4is became available in Denmark in 2007

Retatrutide, Eli Lillys latest weight management and diabetes drug, appears to have outperformed the companys current product, tirzepatide (Mounjaro, Zepbound), in clinical trials

GLP-1 receptor agonists are synthetic molecules engineered to mimic the hormone while resisting breakdown, so the signal lasts hours or days instead

If that holds up in prospective studies, it changes how we think about this disease entirely, and this finding provides a strong rationale for further mechanistic and clinical studies focused on endometrial cancer prevention and treatment. The most dramatic drops in risk, where this reduction was by 50% or more, also occurred in multiple myeloma, pancreatic cancer, and colorectal cancer, in addition to endometrial cancer